30 related articles for article (PubMed ID: 38606590)
1. Multicellular Tumor Spheroids Combined with Mass Spectrometric Histone Analysis To Evaluate Epigenetic Drugs.
Feist PE; Sidoli S; Liu X; Schroll MM; Rahmy S; Fujiwara R; Garcia BA; Hummon AB
Anal Chem; 2017 Mar; 89(5):2773-2781. PubMed ID: 28194967
[TBL] [Abstract][Full Text] [Related]
2. [Epigenetic aberrations in adult T-cell leukemia/lymphoma and development of a novel EZH1/2 inhibitor].
Yamagishi M
Rinsho Ketsueki; 2018; 59(4):432-438. PubMed ID: 29743404
[TBL] [Abstract][Full Text] [Related]
3. Valemetostat: First approval as a dual inhibitor of EZH1/2 to treat adult T-cell leukemia/lymphoma.
Dou F; Tian Z; Yang X; Li J; Wang R; Gao J
Drug Discov Ther; 2022 Dec; 16(6):297-299. PubMed ID: 36310058
[TBL] [Abstract][Full Text] [Related]
4. Targeting Excessive EZH1 and EZH2 Activities for Abnormal Histone Methylation and Transcription Network in Malignant Lymphomas.
Yamagishi M; Hori M; Fujikawa D; Ohsugi T; Honma D; Adachi N; Katano H; Hishima T; Kobayashi S; Nakano K; Nakashima M; Iwanaga M; Utsunomiya A; Tanaka Y; Okada S; Tsukasaki K; Tobinai K; Araki K; Watanabe T; Uchimaru K
Cell Rep; 2019 Nov; 29(8):2321-2337.e7. PubMed ID: 31747604
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of action and resistance in histone methylation-targeted therapy.
Yamagishi M; Kuze Y; Kobayashi S; Nakashima M; Morishima S; Kawamata T; Makiyama J; Suzuki K; Seki M; Abe K; Imamura K; Watanabe E; Tsuchiya K; Yasumatsu I; Takayama G; Hizukuri Y; Ito K; Taira Y; Nannya Y; Tojo A; Watanabe T; Tsutsumi S; Suzuki Y; Uchimaru K
Nature; 2024 Mar; 627(8002):221-228. PubMed ID: 38383791
[TBL] [Abstract][Full Text] [Related]
6. EZH1 mediates methylation on histone H3 lysine 27 and complements EZH2 in maintaining stem cell identity and executing pluripotency.
Shen X; Liu Y; Hsu YJ; Fujiwara Y; Kim J; Mao X; Yuan GC; Orkin SH
Mol Cell; 2008 Nov; 32(4):491-502. PubMed ID: 19026780
[TBL] [Abstract][Full Text] [Related]
7. Unlocking adult T-cell leukemia/lymphoma's epigenetic secrets: delving into the mechanism and impact of EZH1/2 inhibition.
Tavakoli Shirazi P; Bywater MJ
Immunol Cell Biol; 2024; 102(5):298-301. PubMed ID: 38606590
[TBL] [Abstract][Full Text] [Related]
8. The role of EZH1 and EZH2 in development and cancer.
Lee SH; Li Y; Kim H; Eum S; Park K; Lee CH
BMB Rep; 2022 Dec; 55(12):595-601. PubMed ID: 36476271
[TBL] [Abstract][Full Text] [Related]
9. Targeting EZH2 and PRC2 dependence as novel anticancer therapy.
Xu B; Konze KD; Jin J; Wang GG
Exp Hematol; 2015 Aug; 43(8):698-712. PubMed ID: 26027790
[TBL] [Abstract][Full Text] [Related]
10. Dynamics of H3K27me3 methylation and demethylation in plant development.
Gan ES; Xu Y; Ito T
Plant Signal Behav; 2015; 10(9):e1027851. PubMed ID: 26313233
[TBL] [Abstract][Full Text] [Related]
11. Fibrosis-the tale of H3K27 histone methyltransferases and demethylases.
Basta MD; Petruk S; Mazo A; Walker JL
Front Cell Dev Biol; 2023; 11():1193344. PubMed ID: 37476157
[TBL] [Abstract][Full Text] [Related]
12. Role of PRC2-associated factors in stem cells and disease.
Vizán P; Beringer M; Ballaré C; Di Croce L
FEBS J; 2015 May; 282(9):1723-35. PubMed ID: 25271128
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]